tranexamic acid has been researched along with Puerperal Disorders in 5 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Puerperal Disorders: Disorders or diseases associated with PUERPERIUM, the six-to-eight-week period immediately after PARTURITION in humans.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Tranexamic acid (AMCA) is an inhibitor of fibrinolysis used to treat fibrinolytic bleeding (e." | 7.68 | Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. ( Astedt, B; Lindoff, C; Rybo, G, 1993) |
| "Tranexamic acid (AMCA) is an inhibitor of fibrinolysis used to treat fibrinolytic bleeding (e." | 3.68 | Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. ( Astedt, B; Lindoff, C; Rybo, G, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benhamou, D | 1 |
| Keita, H | 1 |
| Ducloy-Bouthors, AS | 1 |
| Bistervels, IM | 1 |
| Scheres, LJJ | 1 |
| Hamulyák, EN | 1 |
| Middeldorp, S | 1 |
| Sekhavat, L | 1 |
| Tabatabaii, A | 1 |
| Dalili, M | 1 |
| Farajkhoda, T | 1 |
| Tafti, AD | 1 |
| Jackson, N | 1 |
| Hashim, ZA | 1 |
| Zainal, NA | 1 |
| Jamaluddin, N | 1 |
| Lindoff, C | 1 |
| Rybo, G | 1 |
| Astedt, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparative Study For Role Of Different Prophylactic Doses Of Intravenous Tranexamic Acid In Reducing Blood Loss At Caesarean Section: A Randomised Controlled Trial[NCT02739815] | Phase 4 | 200 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| Tranexamic Acid Versus Novel Uterine Cooling Technique in Reducing Blood Loss and Incidence of Postpartum Hemorrhage at Caesarean Section[NCT02780245] | Phase 4 | 100 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| The Effect of Local Tranexamic Acid on Post-operative Edema and Ecchymosis in Eyelid Surgery[NCT04951128] | Phase 4 | 50 participants (Anticipated) | Interventional | 2021-08-01 | Not yet recruiting | ||
| Tranexamic Acid in Surgery of Advanced Ovarian Cancer - a Prospective Randomized Double Blind Placebo Controlled Study[NCT00740116] | Phase 4 | 100 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Median number of red blood cells transfused among those who received RBC transfusions (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks
| Intervention | units (Median) |
|---|---|
| The Placebo Group | 2 |
| The Tranexamic Acid Group | 2 |
Total number of RBC-transfused women in each group (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks
| Intervention | participants (Number) |
|---|---|
| Tranexamic Group | 15 |
| Placebo Group | 22 |
Thromboembolic events including arterial thrombosis, muscle vein thrombosis, superficial and deep venous thrombosis. (NCT00740116)
Timeframe: From time of operation to 5 weeks postoperatively.
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Group | 2 |
| Placebo Group | 5 |
Total number of red blood cells (RBC) transfused across all participants (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks
| Intervention | units (Number) |
|---|---|
| Tranexamic Group | 38 |
| Placebo Group | 53 |
Estimation of total blood loss was based on the estimation of the Hb balance method (Brecher, et al.1997) with the assumption that the body blood volume was normalised on the fifth postoperative day. The haemoglobin level was assessed preoperatively and on the fifth postoperative day. The predicted blood volume (PBV, l) was calculated according to the method described by Nadler et al. (1962), using body weight and height. The extravasation of haemoglobin was calculated taking into account allogenic transfused haemoglobin. Total blood loss perioperatively was related to the patient's preoperative haemoglobin value. Blood loss due to haematomas or a reoperation within the first five days after surgery was also considered. (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks
| Intervention | milliliter (Median) |
|---|---|
| Tranexamic Group | 520 |
| Placebo Group | 730 |
2 reviews available for tranexamic acid and Puerperal Disorders
| Article | Year |
|---|---|
Coagulation changes and thromboembolic risk in COVID-19 obstetric patients.
Topics: Anticoagulants; Autoantibodies; Betacoronavirus; Blood Proteins; Cerebrovascular Disorders; Contrain | 2020 |
Sex matters: Practice 5P's when treating young women with venous thromboembolism.
Topics: Adult; Anticoagulants; Contraceptives, Oral, Combined; Disease Susceptibility; Female; Heparin, Low- | 2019 |
1 trial available for tranexamic acid and Puerperal Disorders
| Article | Year |
|---|---|
Efficacy of tranexamic acid in reducing blood loss after cesarean section.
Topics: Adult; Antifibrinolytic Agents; Cesarean Section; Female; Humans; Monitoring, Physiologic; Placebos; | 2009 |
Efficacy of tranexamic acid in reducing blood loss after cesarean section.
Topics: Adult; Antifibrinolytic Agents; Cesarean Section; Female; Humans; Monitoring, Physiologic; Placebos; | 2009 |
Efficacy of tranexamic acid in reducing blood loss after cesarean section.
Topics: Adult; Antifibrinolytic Agents; Cesarean Section; Female; Humans; Monitoring, Physiologic; Placebos; | 2009 |
Efficacy of tranexamic acid in reducing blood loss after cesarean section.
Topics: Adult; Antifibrinolytic Agents; Cesarean Section; Female; Humans; Monitoring, Physiologic; Placebos; | 2009 |
2 other studies available for tranexamic acid and Puerperal Disorders
| Article | Year |
|---|---|
Puerperal acquired factor VIII inhibitor causing a von Willebrand-like syndrome in a patient with anti-DNA antibodies.
Topics: Adult; Antibodies, Antinuclear; Factor VIII; Female; Gingival Hemorrhage; Humans; Lupus Erythematosu | 1995 |
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications.
Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P | 1993 |
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications.
Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P | 1993 |
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications.
Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P | 1993 |
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications.
Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P | 1993 |